- Home
- SAGE vs MUX Comparison
SAGE vs MUX Comparison
Compare SAGE & MUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAGE
- MUX
- Stock Information
- Founded
- SAGE 2010
- MUX 1979
- Country
- SAGE United States
- MUX Canada
- Employees
- SAGE N/A
- MUX N/A
- Industry
- SAGE Biotechnology: Pharmaceutical Preparations
- MUX Precious Metals
- Sector
- SAGE Health Care
- MUX Basic Materials
- Exchange
- SAGE Nasdaq
- MUX Nasdaq
- Market Cap
- SAGE 413.9M
- MUX 435.3M
- IPO Year
- SAGE 2014
- MUX N/A
- Fundamental
- Price
- SAGE $6.46
- MUX $8.03
- Analyst Decision
- SAGE Hold
- MUX Strong Buy
- Analyst Count
- SAGE 19
- MUX 2
- Target Price
- SAGE $9.88
- MUX $14.00
- AVG Volume (30 Days)
- SAGE 815.0K
- MUX 594.8K
- Earning Date
- SAGE 04-29-2025
- MUX 05-07-2025
- Dividend Yield
- SAGE N/A
- MUX N/A
- EPS Growth
- SAGE N/A
- MUX N/A
- EPS
- SAGE N/A
- MUX N/A
- Revenue
- SAGE $47,404,000.00
- MUX $168,945,000.00
- Revenue This Year
- SAGE $103.73
- MUX N/A
- Revenue Next Year
- SAGE $41.15
- MUX N/A
- P/E Ratio
- SAGE N/A
- MUX N/A
- Revenue Growth
- SAGE N/A
- MUX N/A
- 52 Week Low
- SAGE $4.62
- MUX $6.38
- 52 Week High
- SAGE $13.47
- MUX $12.45
- Technical
- Relative Strength Index (RSI)
- SAGE 38.73
- MUX 58.33
- Support Level
- SAGE $6.36
- MUX $7.42
- Resistance Level
- SAGE $6.78
- MUX $8.31
- Average True Range (ATR)
- SAGE 0.24
- MUX 0.24
- MACD
- SAGE -0.01
- MUX 0.09
- Stochastic Oscillator
- SAGE 12.22
- MUX 80.42
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
About MUX McEwen Mining Inc.
McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company primarily generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, most production occurs in the United States.